# Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a public company listed on NYSE as ATNM, headquartered in New York, NY, United States.

## Company overview

- **Legal name:** Actinium Pharmaceuticals, Inc.
- **Former names in filing history:** Cactus Ventures, Inc. (2007-02-05 to 2013-03-29)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** New York, NY, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **Ticker:** NYSE: ATNM
- **SEC CIK:** 0001388320

## About

Actinium Pharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001388320, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-03-30, it reported annual revenue of USD 90,000; net income of USD -33,887,000; total assets of USD 51,775,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $90,000 (USD 90,000)
- **Net income:** -$33.9M (USD -33,887,000)
- **Total assets:** $51.8M (USD 51,775,000)
- **Cash and equivalents:** $48.0M (USD 47,998,000)
- **Operating cash flow:** -$24.6M (USD -24,580,000)

### FY2024 (period ended 2024-12-31)

- **Net income:** -$38.2M (USD -38,243,000)
- **Total assets:** $76.9M (USD 76,899,000)
- **Cash and equivalents:** $72.9M (USD 72,904,000)
- **Operating cash flow:** -$33.1M (USD -33,072,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $81,000 (USD 81,000)
- **Net income:** -$48.8M (USD -48,818,000)
- **Total assets:** $81.4M (USD 81,445,000)
- **Cash and equivalents:** $76.7M (USD 76,677,000)
- **Operating cash flow:** -$47.3M (USD -47,335,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $1.0M (USD 1,030,000)
- **Net income:** -$33.0M (USD -33,017,000)
- **Total assets:** $114.2M (USD 114,192,000)
- **Cash and equivalents:** $108.9M (USD 108,910,000)
- **Operating cash flow:** $8.6M (USD 8,644,000)

## Recent SEC filings

- Form 8-K — filed 2026-08-14 — period 2026-08-12 — CURRENT REPORT
- Form 10-Q — filed 2026-08-07 — period 2026-06-30 — QUARTERLY REPORT
- Form 8-K — filed 2026-06-18 — period 2026-06-18 — CURRENT REPORT
- Form 8-K — filed 2026-05-29 — period 2026-05-27 — CURRENT REPORT
- Form 10-Q — filed 2026-05-08 — period 2026-03-31 — QUARTERLY REPORT
- Form 10-K — filed 2026-03-30 — period 2025-12-31 — ANNUAL REPORT
- Form 8-K — filed 2026-02-13 — period 2026-02-11 — CURRENT REPORT
- Form 8-K — filed 2025-11-26 — period 2025-11-26 — CURRENT REPORT
- Form 10-Q — filed 2025-11-14 — period 2025-09-30 — QUARTERLY REPORT
- Form DEF 14A — filed 2025-11-05 — period 2025-11-26 — PROXY STATEMENT
- Form 10-Q — filed 2025-08-08 — period 2025-06-30 — QUARTERLY REPORT
- Form 10-Q — filed 2025-05-09 — period 2025-03-31 — QUARTERLY REPORT

---

Updated: 2026-10-23T06:09:42Z

Canonical page: https://altss.com/profile/actinium-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology